下一个

自动播放

Dr. Moskowitz on the ALCANZA Trial in CTCL

4 意见 • 08/09/23
分享
嵌入
administrator
administrator
订户
0

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放